The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Sepsis in the Emergency Department: Recognition and the First Hours
- Opioid Use Disorder in the Emergency Department: Buprenorphine Initiation, Naloxone Distribution, and the Warm Handoff on International Overdose Awareness Day
- Dementia in the Emergency Department: Recognizing Delirium, Anticholinergic Burden, and the “Acting Different” Presentation
- Heat-Related Illness in the Emergency Department: Recognition, Cooling, and the High-Risk Patient
- EMS Week in Practice: Strengthening the Prehospital-to-ED Continuum for Better Patient Outcomes